ribavirin has been researched along with Ascites in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Bary, HM; El Sayed, IET; Ghanm, SE; Othman Saad, W; Saad, BF; Shebl, NA | 1 |
| Bian, E; Hao, L; Huang, X; Tian, Y; Wu, Y; Yang, R; Yang, W; Yang, Y; Zhang, B; Zhang, Q | 1 |
| Basha, MAA; Bassiony, MA; Hanafy, AS | 1 |
| Dultz, G; Friedrich-Rust, M; Herrmann, E; Hofmann, WP; Kronenberger, B; Sarrazin, C; Seelhof, M; Teuber, G; Vermehren, J; von Wagner, M; Welker, MW; Zeuzem, S | 1 |
| Acosta Materan, R; Martín Arribas, MI; Mora Soler, AM; Pérez Corte, D; Revilla Morato, C; Rodríguez Pérez, A; Velasco-Guardado, A | 1 |
5 other study(ies) available for ribavirin and Ascites
| Article | Year |
|---|---|
Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus.
Topics: Adult; Aged; Antiviral Agents; Ascites; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interleukin-10; Liver Cirrhosis; Liver Neoplasms; Lymphadenitis; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Splenomegaly; Valine | 2021 |
Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5.
Topics: Animals; Antimetabolites, Antineoplastic; Ascites; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Epigenesis, Genetic; Eukaryotic Initiation Factor-4E; Humans; Liver Neoplasms; Mice; Protein-Arginine N-Methyltransferases; Ribavirin; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2022 |
Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?
Topics: Adult; Antiviral Agents; Ascites; Carbamates; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Patient Selection; Pyrrolidines; Quality of Life; Ribavirin; RNA, Viral; Severity of Illness Index; Sofosbuvir; Survival Rate; Sustained Virologic Response; Ultrasonography; Valine | 2019 |
Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Ascites; Disease Progression; Female; Follow-Up Studies; Hemorrhage; Hepatitis C, Chronic; Hospitalization; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk; Withholding Treatment | 2013 |
[Chronic hepatitis caused by hepatitis E virus and treated with ribavirin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Ascites; Enterobacteriaceae Infections; Female; Hafnia alvei; Hematopoietic Stem Cell Transplantation; Hepatitis E; Hepatitis E virus; Hepatitis, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Middle Aged; Ribavirin; Rituximab; Transplantation, Autologous | 2016 |